Literature DB >> 2900174

The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation.

A Faundes1, F Alvarez, V Brache, A S Tejada.   

Abstract

Hematocrit and blood ferritin were assayed in 43 women using a levonorgestrel intrauterine device (LevoNg-IUD), 49 using the Copper T-380 Ag (T-Cu 380 Ag), 27 using the Lippes loop and 30 non-IUD users as controls. The mean duration of use was 41 months for the three IUD groups. Women not using IUDs and with similar age, parity, years of schooling and family income as users had a normal mean hematocrit and ferritin, but 30% had low hematocrit (below 38%) and 43% had low ferritin (below 11 ng/ml). After prolonged use of the IUDs, 26% of users of Lippes loop, 22% of users of T-Cu 380 Ag and only 2% of users of LevoNg-IUD had subnormal hematocrit; 70%, 55% and 14%, respectively, had low ferritin. Thus, in a population with high incidence of anemia, the use of LevoNg-IUD appears to reduce the proportion of women with clinical anemia and with depletion of their iron store.

Entities:  

Keywords:  Americas; Biology; Caribbean; Comparative Studies; Contraception; Contraceptive Agents, Female--beneficial effects; Contraceptive Agents, Progestin--beneficial effects; Contraceptive Agents--beneficial effects; Contraceptive Methods; Developed Countries; Developing Countries; Dominican Republic; Endocrine System; Evaluation; Examinations And Diagnoses; Family Planning; Health; Hematological Effects; Hemic System; Hemoglobin Level--changes; Hormones; Iud; Iud, Copper Releasing; Iud, Unmedicated; Laboratory Examinations And Diagnoses; Latin America; Levonorgestrel--beneficial effects; North America; Nutrition; Physiology; Reproductive Control Agents; Research Methodology; Research Report; Serum Iron Level--changes; Studies

Mesh:

Substances:

Year:  1988        PMID: 2900174     DOI: 10.1016/0020-7292(88)90341-4

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  4 in total

Review 1.  A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.

Authors:  F Sturridge; J Guillebaud
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

2.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Utility of the Levonorgestrel-Releasing Intrauterine System in the Treatment of Abnormal Uterine Bleeding and Dysmenorrhea: A Narrative Review.

Authors:  Paola Bianchi; Sun-Wei Guo; Marwan Habiba; Giuseppe Benagiano
Journal:  J Clin Med       Date:  2022-10-01       Impact factor: 4.964

4.  Levonorgestrel-releasing intrauterine system and iron overload syndrome.

Authors:  Marcia Vieira da Motta; Eduardo Vieira da Motta
Journal:  Clin Med Insights Case Rep       Date:  2013-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.